R-phenserine

Drug Profile

R-phenserine

Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; Posiphen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
  • Developer Cenomed BioSciences; QR Pharma; Rockefeller University; University of California at Los Angeles
  • Class Nootropics; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Mild cognitive impairment; Parkinson's disease
  • Preclinical Huntington's disease
  • No development reported Brain injuries; Poisoning

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain injuries in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Poisoning in USA (PO)
  • 16 Mar 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease and Parkinson's disease released by QR Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top